Loading clinical trials...

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

A Phase 1 Study Of Cmc-544 Administered As A Single Agent In Subjects With B-cell Non- Hodgkin's Lymphoma

NCT00073749•Pfizer

Summary

To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).

Eligibility

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects who have been previously diagnosed with CD22-positive, B-cell NHL, according to WHO classification, which has progressed after at least 2 prior therapies of probable clinical benefit
•At the expanded cohort, part 2 of the study, subjects must have one of the following:
•Follicular lymphoma previously treated with at least one dose of rituximab, but have not received radioimmunotherapy
•Diffuse large B-cell lymphoma
•Age 18 years or older

Exclusion Criteria

•Candidate for potentially curative therapies in the opinion of the investigator
•Chronic lymphocytic leukemia
•Burkitt's lymphoma, primary effusion lymphoma, and precursor B-cell lymphoblastic lymphoma

Locations (22)

UAB CCC Clinical Studies Unit

Birmingham, Alabama, United States

University of Alabama at Birmingham Kirklin Clinic

Birmingham, Alabama, United States

UAB Russell Ambulatory Pharmacy

Birmingham, Alabama, United States

University of Alabama at Birmingham

Birmingham, Alabama, United States

Northwestern Medical Faculty Foundation

Chicago, Illinois, United States

Northwestern Memorial Hospital

Chicago, Illinois, United States

Roswell Park Cancer Institute

Buffalo, New York, United States

The Cleveland Clinic Foundation

Cleveland, Ohio, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

August 1, 2003

Primary Completion Date

December 1, 2010

Completion Date

December 1, 2010

Last Updated

December 17, 2018

Enrollment

ACTUAL participants

Conditions

Lymphoma, B-Cell

Interventions

Inotuzumab ozogamicin [CMC-544]

DRUG

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

NCT04161248

Lymphoma, B-Cell

View study

RECRUITINGPHASE1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

NCT06528301

Lymphoma, B-CellLymphoma, Non-Hodgkin (NHL)+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 17, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Inclusion Criteria

Exclusion Criteria

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma